## DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION DISTRICT ADDRESS AND PHONE NUMBER 22215 26th Ave SE Suite 210 5/28/2019-6/13/2019\* Bothell, WA 98021 3006089725 (425)302-0340 Fax: (425)302-0404 NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Hee Joo Park, President and CEO 530 S 336th St Puget Sound Drug Corporation dba Key Pharmacy and Compounding Center CITY, STATE, ZIP CODE, COUNTRY TYPE ESTABLISHMENT INSPECTED Federal Way, WA 98003-6383 Producer of sterile and non-sterile products

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

## DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:

## OBSERVATION 1


You used a non-pharmaceutical grade component in the formulation of a drug product.

Specifically,

Your firm uses non-pharmaceutical grade corn syrup in the production of veterinary drug products. For example, on 5/21/2019, your firm produced Potassium Bromide (vet) Beef 250 mg/mL soln, lot 05/20/2019@72 using corn syrup that is not labeled as pharmaceutical or FCC grade. The label of the corn syrup you used lists ingredients in addition to corn syrup.

## \*DATES OF INSPECTION

5/28/2019(Tue), 5/29/2019(Wed), 5/30/2019(Thu), 5/31/2019(Fri), 6/03/2019(Mon), 6/04/2019(Tue), 6/05/2019(Wed), 6/06/2019(Thu), 6/07/2019(Fri), 6/13/2019(Thu)



EMPLOYEE(S) SIGNATURE Andrew K Haack, Investigator Peter S Kessler, Investigator	Andrew K Haeck Investigator Styned By: Andrew K. Haack -S Date Styned: 06-113-2019 07:27-43	DATE ISSUED 6/13/2019

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

INSPECTIONAL OBSERVATIONS

PAGE 1 of 1 PAGES